Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology
21 janv. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced a hereditary cancer risk assessment program study was published in Obstetrics & Gynecology (also known as The Green Journal).
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance
15 janv. 2025 08h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announces select preliminary fourth quarter and full year 2024 financial results and introduces full year 2025 financial guidance.
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
09 janv. 2025 16h30 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced it signed an agreement with sports broadcaster Hannah Storm to promote the importance of knowing family cancer history.
UPDATE – Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 11h27 HE
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
08 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
Paul J. Diaz, President and CEO, and Sam Raha, COO, Myriad Genetics, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference.
MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad’s molecular residual disease assay
07 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
The University of Texas MD Anderson Cancer Center and Myriad Genetics announced a five-year strategic alliance.
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
06 janv. 2025 08h00 HE
|
Myriad Genetics, Inc.
Myriad Genetics released its Quality, Innovation, and Corporate Responsibility Report.
Myriad Genetics’ RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
19 déc. 2024 16h15 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced a MyRisk® Hereditary Cancer Test with RiskScore® study was named as one of the top 10 significant advances in genomic medicine.
Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
10 déc. 2024 18h26 HE
|
Myriad Genetics, Inc.
Myriad Genetics provides update on discussions with UnitedHealthcare regarding medical policy for pharmacogenetic testing.
Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member
10 déc. 2024 16h05 HE
|
Myriad Genetics, Inc.
Myriad Genetics announced the election of Mark S. Davis to its Board of Director, effective immediately, expanding the Board from eight to nine members.